Genetic knockout of FGF19 or inhibition of FGFR4 has been demonstrated to inhibit breast tumor progression and metastasis in mouse models, suggesting that targeting FGFR4 may be a viable therapeutic strategy for cancer suppression. This evidence concerns the gene FGF19 and breast neoplasm.